ArticleJournal of thoracic disease2025
Prognosis of critically ill immunocompromised patients with COVID-19 admitted for acute respiratory failure: a retrospective propensity score analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathogen distribution and prognostic risk factors in respiratory intensive care unit (RICU) patients of a large general hospital before and after COVID-19 pandemic.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Since the introduction of coronavirus disease 2019 (COVID-19) vaccination, the proportion of immunocompromised patients among critically ill individuals admitted to the intensive care unit (ICU) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia seems to have increased significantly. However, data on this specific critically ill population remain limited. The aim of our study is to explore the impact of immunocompromised status on ICU outcomes in COVID-19 patients admitted for acute respiratory failure (ARF). Methods: In this retrospective study, data from adult patients admitted for ARF-related to SARS-CoV-2 pneumonia were collected. To study the impact of immunocompromised status, immunocompromised and non-immunocompromised patients were matched using propensity scores. A Cox-proportional hazard model was used to determine whether immunocompromised status during the ICU stay was associated with ICU mortality. Results: Between March 2021, the time of admission of the first vaccinated patients, and December 2022, we identified 294 patients (220 non-immunocompromised, 74 immunocompromised). The immunocompromised group had a greater risk of mortality in the ICU (31.1% Conclusions: After adjustment for prognostic variables, the immunocompromised status of patients admitted to the ICU for SARS-CoV-2-related ARF was not associated with increased mortality, despite a significantly longer ICU stay and a greater rate of ICU acquired infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.